LifeArc Ventures

LifeArc is #hiring. Looking for an experienced protein scientist who is passionate about producing high quality proteins for use in small molecule drug discovery...

Thank you to everyone who joined us for the BioIndustry Association (BIA)'s 24th annual Parliament Day yesterday 👏 We had a great time engaging in meaningful discussions with #Policymakers on the critical role of the UK #LifeScience 🧬 sector in yesterday’s sessions and shared valuable insights. We look forward to continuing these important conversations and working together to drive innovation and 💰 #Investment in the sector. #BIAinParliament 

LifeArc Ventures' team will be out and about during London Life Sciences Week (LLSW), November 17 - 21 2024, including LSX - partnering for Life Science eXecutives #Investival Showcase on November 18 and Jefferies London Healthcare Conference November 19-21 #jefferieshealthcare. LifeArc BioIndustry Association (BIA) MedCity #LondonLifeSciencesWeek #LLSW2024

Great to meet Emily Darlington MP to discuss the vital role that life sciences has in securing economic growth and driving benefits for patients. The regular dialogue between the BIA and our politicians and policy makers is essential to ensuring we enable our industry to achieve its full potential.

This morning, Maddie Cass and BIA members met with Emily Darlington MP, a Member of the Science, Innovation and Technology Committee, for discussions on strengthening #UK #LifeSciences. Key topics included: 👉 Driving growth through public and private #Investment in UK life sciences 👉 Building a pro-innovation NHS equipped for the future 👉 Reinforcing and promoting UK strengths in life sciences to seize #Global opportunities 🌍 📌 Paul Varley, Chief Development Officer, Alchemab Therapeutics Ltd 📌 Pete Tonge, Senior Director of Cell Therapy Enginering, bit.bio 📌 Clare Terlouw, Head of LifeArc Ventures, LifeArc 📌 Adam Glen, Founder, Unicorn Biotechnologies #BIAinParliament

📣 The BioIndustry Association (BIA)'s 24th annual Parliament Day is taking place today! The day began with a breakfast briefing led by BIA CEO Steve Bates OBE FMedSci, Associate Director for Policy, Public Affairs and Investor Relations Dr Martin Turner, and Senior Policy and Public Affairs Manager Rosie Lindup 👏 We are looking forward to a jam-packed day with meetings with #Policymakers to discuss our three key priorities: 📌 Delivering growth 📌 Enabling a pro-innovation NHS fit for the future 📌 Reinforcing and promoting #UK strengths in #LifeSciences #BIAinParliament

📣 Senior Manufacturing Programme Executive Abby Clark joined Adam Thompson MP to discuss essential topics for the UK #LifeSciences sector, including access to scaling capital, innovation #Investment📈, R&D funding, and the role of public investment markets 💰 We were joined by BIA members ⤵ 📌 Paul Varley, Chief Development Officer, Alchemab Therapeutics Ltd 📌 Clare Terlouw, Head of LifeArc Ventures  📌 Edward Green, Chief Executive, NCIMB Ltd · 📌 Prashant Shah, CEO, o2h discovery 📌 Iain McGill, CEO, Quell Therapeutics #BIAinParliament

We can’t wait for this year’s UK tech awards 2024 ceremony taking place this Thursday!   In the fast-paced tech sector, it’s a rare and wonderful opportunity to come together, network, and celebrate the remarkable achievements of the UK tech community.   We’re honored to be shortlisted for the Tech Innovation of the Year Award—a recognition that strengthens our commitment at Closed Loop Medicine to advancing precision medicine for all, one milligram at a time.   Good luck to all the other nominees: Bramble Energy Limited, Diaceutics PLC, Featurespace, Luminance Technologies, and Pragmatic Semiconductor!   #UKTech24 #Shortlist #TechBio #Innovation

We are thrilled to announce that we are committing £5 million over the next 5 years to establish a new Centre for Translational AMR Research (CTAR) at the University of Cape Town's Drug Discovery and Development Centre (H3D), University of Cape Town. The CTAR Programme will combine the unique strengths of LifeArc and H3D to tackle AMR, by supporting the development of first-in-class treatments for multidrug-resistant infections. It will focus on gram-negative bacteria like Acinetobacter baumannii, which is one of the World Health Organization's "priority pathogens" due to its significant threat to public health. The programme also aims to help support local research capacity in Africa, where the incidence and impact of microbial resistance are widespread. We will provide H3D with multidisciplinary support, training and scientific placements to help strengthen research capabilities. Recent studies estimate that 1.91 million people each year will die as a direct result of AMR by 2050. This means that 39 million people will lose their lives between 2025 and 2050 if we don't act now. The CTAR programme demonstrates our ongoing commitment to combating resistant infections and saving lives. Read more here: https://lnkd.in/eCQ4EtYe #AntimicrobialResistance #GlobalHealth #AMR #DrugDiscovery

More venture capital has been invested in UK biotech so far this year than the whole of 2023, and we long surpassed last year's public financing total too. Those green shoots are pushing through the parched earth. The BioIndustry Association (BIA) Q3 finance report is out. Well done Wendy Quainoo and Saqib Lal for getting this report out just three weeks after the quarter end. Speedy work! Read it here: https://lnkd.in/eyUN-SY4 #biotech #lifesciences #finance #investment